Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven H Stein

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Annals of Internal Medicine|September 24, 2004
Update in oncologySteven H Stein
Annals of Internal Medicine|October 22, 2003
Update in oncologySteven H Stein
Journal of Clinical Apheresis|July 23, 2003
Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpuraNicole A Aqui, Steven H Stein, Barbara A Konkle, et al.
Cancer Research|February 7, 2007
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancersWenle Xia, Intisar Husain, Leihua Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancerColin F Spraggs, Laura R Budde, Linda P Briley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancerAngelo Di Leo, Henry L Gomez, Zeba Aziz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2008
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancerHenry L Gomez, Dinesh C Doval, Miguel A Chavez, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Annals of Internal Medicine|September 24, 2004
Update in oncologySteven H Stein
Annals of Internal Medicine|October 22, 2003
Update in oncologySteven H Stein
Journal of Clinical Apheresis|July 23, 2003
Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpuraNicole A Aqui, Steven H Stein, Barbara A Konkle, et al.
Cancer Research|February 7, 2007
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancersWenle Xia, Intisar Husain, Leihua Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancerColin F Spraggs, Laura R Budde, Linda P Briley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancerAngelo Di Leo, Henry L Gomez, Zeba Aziz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2008
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancerHenry L Gomez, Dinesh C Doval, Miguel A Chavez, et al.
Pageof 1